Bristol-Myers Squibb Company
Treatment of Hodgkin lymphoma using an anti-PD-1 antibody

Abstract:

This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.